why choose us

First received: August 30, 2023

Clinical Trial: Siplizumab for Sickle Cell Disease Transplant

Study Status: Completed

Recruit Status: RECRUITING

Condition: Anemia, Sickle Cell

Study Type: INTERVENTIONAL


Official Title: Siplizumab-based Conditioning for Hematopoietic Stem Cell Transplantation in Patients With Advanced Sickle Cell Disease (CD2 SCD)

Brief Summary: The purpose of this study is to find out whether siplizumab is safe and effective for patients with SCD undergoing an allogeneic transplant and to prevent development of Graft versus Host Disease (GVHD) and graft failure.The main goals of this study are :To determine if acute GVHD occurs and how severe the acute GVHD is in subjects receiving the study drugTo determine if graft failure occurs in subjects receiving the study drugsIn this study, participants will receive 5 infusions of the study drug, siplizumab,…

Read more